-
Product Insights
Cytotoxic T Lymphocyte Protein 4 – Drugs In Development, 2023
Global Markets Direct’s Cytotoxic T Lymphocyte Protein 4 provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic...
-
Sector Analysis
NewPersonal Hygiene Market Opportunities, Trends, Growth Analysis and Forecast to 2028
Personal Hygiene Market Report Overview The personal hygiene market size was valued at $63.8 billion in 2023 and is likely to grow at a CAGR of more than 4% from 2023 to 2028. The growing consumer awareness of the importance of personal hygiene, especially during the COVID-19 pandemic, has supported the sector’s sales growth. Natural and plant-based ingredients in personal hygiene products have garnered significant interest, resulting in high demand for products bearing tags such as paraben-free and sulfate-free. Personal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Mogamulizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mogamulizumab in Oral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mogamulizumab in Oral Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mogamulizumab in Oral Cancer Drug Details: Mogamulizumab (Poteligeo) is a glyco-engineered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Nanatinostat + Valganciclovir) in Epstein–Barr Virus (HHV-4) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Nanatinostat + Valganciclovir) in Epstein–Barr Virus (HHV-4) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Nanatinostat + Valganciclovir) in Epstein–Barr Virus (HHV-4) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YTE-001 in Epstein–Barr Virus (HHV-4) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YTE-001 in Epstein–Barr Virus (HHV-4) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YTE-001 in Epstein–Barr Virus (HHV-4) Infections Drug Details: Gene therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Burkitt Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...